News

Tracer compounds with high affinity and selectivity to alpha-synuclein deposits have been identified that could be used to detect and track Parkinson’s disease progression, AC Immune announced. Findings were recently presented in the study, “Identification and Characterization of Selective and High Affinity Small Molecules for Positron Emission…

In partnership with the Edmond J. Safra Foundation, The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has announced five academic centers chosen for the Edmond J. Safra Fellowship in Movement Disorders to train the Class of 2022. Each year, the five-year-old fellowship provides funding to five research centers…

An investigational gene therapy being developed for the treatment of Parkinson’s disease was well-  tolerated and eased patients’ motor fluctuations in a dose-dependent manner after a one-time administration, according to interim results. The study, “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson’s Disease,” was…

A new Phase 1/2a clinical trial will investigate resTORbio’s therapy candidate RTB101, alone or in combination with sirolimus, as a potential treatment for Parkinson’s disease. Researchers plan to enroll 45 patients with mild Parkinson’s disease, both with and without mutations in the GBA gene, and who are being treated…

Crystals of the LRRK2 protein grown aboard the International Space Station could improve the understanding of Parkinson’s disease and help develop more effective therapies for this disease, according to researchers. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson’s and result in…

A fear of the potential side effects of Parkinson’s disease treatments, dubbed “levodopa phobia,” can cause patients and their doctors to delay the use of these therapies, a neurologist says. However, evidence suggests that starting adequate levodopa therapy early is safe, particularly for patients with increased functional disability, according…

Abbott has announced promising preliminary results from the PROGRESS trial (NCT02989610) evaluating its Infinity Deep Brain Stimulation (DBS) System for the treatment of Parkinson’s disease. The initial results, detailed in a press release, suggest that the DBS system achieved its primary goal of broadening the “therapeutic window” — the…

Researchers are conducting a study assessing the use of different motion-tracking sensors to remotely gather data from Parkinson’s disease patients. The technology holds the potential to noninvasively monitor Parkinson’s motor symptoms, as well as the effects of medication, over the course of patients’ normal daily lives at home. The…

Parkinson’s disease patients with mild cognitive impairment (MCI) have a lower quality of life if their memory is impaired, according to a study that also revealed that MCI is associated with more severe attention and memory dysfunction in people with the disease. The study, “Mild…

Urate, a salt derived from uric acid, and homocysteine, an amino acid, may predict motor and cognitive decline in early Parkinson’s disease, researchers report. The study with that finding, “Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson’s Disease” was published in the Journal…